• Explore /
  • Poster
  • / Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.

Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.

Abstract Poster

Authors

Jose Mauricio Mota

Jose Mauricio Mota

Instituto D'Or de Pesquisa e Ensino, Sao Paulo, Brazil

Jose Mauricio Mota , Camila Mosci , Jéssica Vasconcellos , Thiago Souto Hemerly , Deusdedit Cortêz Vieira Silva Neto , Luis Felipe Brandao , Victor Srougi , Rodrigo Nalio Ramos , Isabela Werneck Cunha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Diagnostics and Imaging

Clinical Trial Registration Number

NCT05900973

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS348)

DOI

10.1200/JCO.2024.42.4_suppl.TPS348

Abstract #

TPS348

Poster Bd #

Q22

Abstract Disclosures

Similar Posters

First Author: Junlong Zhuang

First Author: A. Oliver Sartor

Poster

2020 Genitourinary Cancers Symposium

Prospective comparison of 68Ga-RM2 PET/CT and 68Ga-PSMA-617 PET/CT for initial staging of prostate cancer.

Prospective comparison of 68Ga-RM2 PET/CT and 68Ga-PSMA-617 PET/CT for initial staging of prostate cancer.

First Author: Romain Schollhammer Sr.

First Author: Aneesh Dhar